Stock Market Reviews

Read and share opinions on STAA (STAAR Surgical Company) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• New $17 Million Bet on STAAR Surgical Comes as Sales Jump 7% and Margins Hit 82%
  Dec 30, 2025
• Exclusive: STAAR merger with Alcon still fails to gain traction, only 30% vote for
  Dec 19, 2025
• Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
  Dec 19, 2025
• Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
  Dec 19, 2025
• Broadwood sees $50/share path for STAAR Surgical as merger battle nears voting day
  Dec 17, 2025
• Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
  Dec 17, 2025
• Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
  Dec 17, 2025
• STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
  Dec 17, 2025
• ISS recommends STAAR Surgical deal, but warns shareholders have reason to object
  Dec 16, 2025
• Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
  Dec 16, 2025
• Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
  Dec 16, 2025
• Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
  Dec 16, 2025
• Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote "FOR" Alcon Merger
  Dec 15, 2025
• Battle for STAAR Surgical intensifies as Glass Lewis reiterates stance ’against’
  Dec 12, 2025
• Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation "AGAINST" STAAR Surgical Sale to Alcon
  Dec 12, 2025
• STAAR Surgical accuses activist Broadwood of ’misinformation campaign’
  Dec 12, 2025

STAA News

• 3 Low-Volatility Stocks We Keep Off Our Radar
  Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
  Dec 29, 2025
• What a $22 Million Bet on STAAR Surgical Signals After Third-Quarter Earnings and a 15% Market Lag
  The stock is roughly flat this past year, but the fundamentals quietly moved in the right direction, and that disconnect likely caught this fund’s attention.
  Dec 23, 2025
• 3 Cash-Heavy Stocks We Keep Off Our Radar
  A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
  Dec 22, 2025
• Exclusive: STAAR merger with Alcon still fails to gain traction, only 30% vote for
  Investing.com -- Amid a highly contentious merger process marked by rampant opposition, the deciding shareholder meeting in STAAR Surgical’s (NASDAQ:STAA) $1.6 billion sale to Alcon AG (NYSE:ALC) has been postponed for a fourth time as the companies fail to win shareholder support.
  Dec 19, 2025
• Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
  LAKE FOREST, Calif., December 19, 2025--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement (the "Special Meeting"). As a result, the Special Meeting, which was scheduled for December 19, 2025 at 8:30 a.m. Pacific Time, has been adjourned to Janu
  Dec 19, 2025
• Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
  NEW YORK, December 19, 2025--Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which together own 30.2% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), today responded to the fourth postponement of STAAR’s Special Meeting of Shareholders (the "Special Meeting") in connection with the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE: ALC).
  Dec 19, 2025
• Broadwood sees $50/share path for STAAR Surgical as merger battle nears voting day
  Investing.com -- The civil war over STAAR Surgical Company (NASDAQ:STAA) raged Wednesday as the lens maker’s largest shareholder, Broadwood Partners, announced it sees a path to a $50-per-share valuation for the company, nearly double the current market price, just two days before a pivotal shareholder vote on a $1.6 billion buyout from Alcon AG (NYSE:ALC).
  Dec 17, 2025
• STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
  LAKE FOREST, Calif., December 17, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following open letter to STAAR stockholders:
  Dec 17, 2025
• Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
  NEW YORK, December 17, 2025--Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today issued the following letter to the Board of Directors (the "Board") of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to urge its fellow shareholders to vote "AGAINST" the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE: ALC).
  Dec 17, 2025
• Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
  Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement reiterating its intention to vote AGAINST the Company's proposed sale to Alcon Inc. ("Alcon") (NYSE: ALC) and expressing its disappointment in the Company's Board of Directors' (the "Board") continued pursuit of the deal:
  Dec 17, 2025
• ISS recommends STAAR Surgical deal, but warns shareholders have reason to object
  Investing.com -- The protracted, $1.6 billion dollar saga over STAAR Surgical Company (NASDAQ:STAA) is entering its final, chaotic phase with the acquisition by Alcon AG (NYSE:ALC) now hinged on a deeply fractured shareholder vote on December 19. The market’s uncertainty peaked Tuesday after leading independent proxy advisory firm Institutional Shareholder Services (ISS) issued its recommendation, casting doubt on whether the controversial merger will pass with shareholders.
  Dec 16, 2025
• Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
  HONG KONG, December 16, 2025--Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), today released the following letter to STAAR shareholders in response to the updated reports of Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co., LLC ("Glass Lewis") regarding the proposed acquisition of STAAR by Alcon Inc. ("Alcon"
  Dec 16, 2025
• Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
  NEW YORK, December 16, 2025--Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today commented on a report published by Institutional Shareholder Services Inc. ("ISS"), an independent proxy advisory firm, which reiterates that firm’s significant concerns regarding the proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) by Alcon Inc. ("Alcon") (NYSE: ALC).
  Dec 16, 2025
• Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
  LAKE FOREST, Calif., December 16, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported that independent industry analysts have recognized the value provided to STAAR stockholders by the Company’s amended merger agreement with Alcon (SIX/NYSE: ALC) and the merits of the Alcon transaction. The Alcon merger agreement, as revised on December 9, 2025, provides that STAAR stock
  Dec 16, 2025
• Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote "FOR" Alcon Merger
  LAKE FOREST, Calif., December 15, 2025--STAAR Surgical Company (NASDAQ: STAA) ("STAAR"), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has issued a new report and revised its recommendation with respect to STAAR’s merger with Alcon. ISS is now recommending that all STAAR stockholders vote "FOR" STAAR’s amended merger agre
  Dec 15, 2025
• Battle for STAAR Surgical intensifies as Glass Lewis reiterates stance ’against’
  Investing.com -- The high-stakes standoff over the $1.6 billion acquisition of STAAR Surgical Company (NASDAQ:STAA) by Alcon AG (NYSE:ALC) continued heightening Friday. Leading proxy advisory firm Glass Lewis reaffirmed its recommendation that shareholders reject the deal, as STAAR management and its largest shareholder, activist firm Broadwood Partners, engaged in an increasingly personal war of words. With the final shareholder vote looming on December 19, the battle has devolved into a series
  Dec 12, 2025
• Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation "AGAINST" STAAR Surgical Sale to Alcon
  NEW YORK, December 12, 2025--Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, has reaffirmed its recommendation that shareholders of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) should vote "AGAINST" the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE: ALC).
  Dec 12, 2025
• STAAR Surgical accuses activist Broadwood of ’misinformation campaign’
  Investing.com -- The contested $1.6 billion merger of STAAR Surgical Company (NASDAQ:STAA) and Alcon AG (NYSE:ALC) escalated again today as the December 19 shareholder vote approaches. STAAR launched a blistering counter-attack against activist shareholder Broadwood Partners, which holds a 30.2% stake, accusing it of manufacturing a "misinformation campaign" regarding a supposed superior bidder during the now passed "go-shop" period. The go-shop period, amended into the deal amid rampant shareho
  Dec 12, 2025
• 1 Russell 2000 Stock Worth Investigating and 2 We Find Risky
  Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
  Dec 11, 2025
• STAAR Surgical Says No 'Credible Buyer' During Go-Shop Process in Alcon Deal
  STAAR Surgical (STAA) refuted Thursday investor Broadwood Partners' allegations, saying there was no
  Dec 11, 2025
• Why STAAR Surgical (STAA) Stock Is Up Today
  Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 3.9% in the morning session after the company issued a statement to defend its pending merger process with Alcon against claims from activist investors.
  Dec 11, 2025
• Sector Update: Health Care Stocks Advance Late Afternoon
  Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta
  Dec 11, 2025
• STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
  LAKE FOREST, Calif., December 11, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement to correct misinformation regarding its robust go-shop process to evaluate available alternatives to the pending merger with Alcon (SIX/NYSE: ALC).
  Dec 11, 2025
• STAAR Surgical (STAA): Assessing Valuation After Recent Share Price Weakness
  STAAR Surgical (STAA) has quietly slipped about 5% in the past week and roughly 13% over the past month, even as annual revenue and net income growth remain firmly positive. This creates an interesting tension for investors. See our latest analysis for STAAR Surgical. Zooming out, the latest 1 month share price return of negative 12.45 percent and 1 year total shareholder return of negative 5.51 percent suggest momentum has been fading even as fundamentals point to longer term growth...
  Dec 11, 2025
• Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
  NEW YORK, December 11, 2025--Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood," "we," "us" or "our") today reacted to the proxy statement supplement filed by STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) with respect to the proposed acquisition of the Company by Alcon Inc. ("Alcon") (NYSE: ALC). In addition, Broadwood released a new presentation explaining why it continues to oppose the proposed transaction, which can be viewed here.
  Dec 11, 2025
• STAAR Surgical falls as Yunqi Capital reiterates opposition to merger with Alcon
  Investing.com -- STAAR Surgical Company (NASDAQ:STAA) shares ticked down 5.5% on Wednesday, reversing some of the previous day’s gains, as another major institutional investor, Yunqi Capital, reaffirmed its opposition to the revised, higher takeover offer from Alcon AG (NYSE:ALC). The $1.6 billion all-cash deal, which was sweetened to $30.75 per share from $28 to quell a fierce shareholder revolt, now faces a multi-front opposition just nine days before the decisive shareholder vote on December
  Dec 10, 2025
• Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
  HONG KONG, December 10, 2025--Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), today released the following letter to STAAR shareholders regarding the closing of STAAR’s go-shop period and the revised offer of Alcon Inc. (SIX/NYSE: ALC) to acquire STAAR for $30.75 per share.
  Dec 10, 2025
• What Makes Staar Surgical (STAA) a New Buy Stock
  Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Dec 9, 2025
• Alcon bumps STAAR Surgical bid to $30.75, but Broadwood remains vehemently against
  Investing.com -- The high-stakes acquisition of STAAR Surgical Company (NASDAQ:STAA) reached a critical juncture today as Alcon AG (NYSE:ALC) announced an amended merger agreement, raising its all-cash offer to $30.75 per share, up from the original $28. The approximately $1.6 billion deal, an attempt to secure shareholder support ahead of the December 19 vote, immediately sent STAAR shares soaring over 15% in morning trading. That number ticked down by 5% once activist shareholder Broadwood Par
  Dec 9, 2025
• STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know
  Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 9.8% in the afternoon session after its merger partner, Alcon, increased its cash buyout offer for the company. Under the amended agreement, Alcon raised its bid from $28.00 to $30.75 per share, boosting the medical technology firm's total value to $1.6 billion. This represented an additional $150 million in equity value for STAAR's stockholders. The new, higher offer came after a "go-shop" period, where STAAR Surgical was permit
  Dec 9, 2025
• Alcon Announces Amended Merger Agreement with STAAR Surgical
  GENEVA, December 09, 2025--Alcon Announces Amended Merger Agreement with STAAR Surgical
  Dec 9, 2025
• Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
  NEW YORK, December 09, 2025--Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood," "we," "us" or "our") today responded to the amended transaction terms of the proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) by Alcon Inc. ("Alcon") (NYSE: ALC).
  Dec 9, 2025
• Sector Update: Health Care Stocks Fall Late Afternoon
  Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the
  Dec 8, 2025
• Why STAAR Surgical (STAA) Shares Are Plunging Today
  Shares of medical lens company STAAR Surgical (NASDAQ:STAA) fell 7.1% in the afternoon session after the company announced the expiration of its 'go-shop' period without receiving any competing acquisition proposals, solidifying its pending merger agreement with Alcon Inc.
  Dec 8, 2025
• Sector Update: Health Care Stocks Lower in Afternoon Trading
  Health care stocks declined Monday afternoon, with the NYSE Health Care Index down 1% and the Health
  Dec 8, 2025
• STAAR Surgical Says Go-Shop Period in Alcon Deal Expires With No Competing Proposals
  STAAR Surgical (STAA) said Monday the go-shop period under its merger agreement with Alcon (ALC) has
  Dec 8, 2025
• Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote "AGAINST" Sale to Alcon
  NEW YORK, December 08, 2025--Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today announced that leading proxy advisory firm Egan-Jones Ratings Company ("Egan-Jones") has reaffirmed its recommendation that shareholders vote "AGAINST" the proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) by Alcon Inc. ("Alcon") (NYSE: ALC) on the GREEN Proxy Card.
  Dec 8, 2025
• STAAR Surgical Announces Expiration of Go-Shop Period
  LAKE FOREST, Calif., December 08, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the previously announced go-shop period pursuant to STAAR’s amended merger agreement with Alcon Inc. (SIX/NYSE: ALC). The go-shop period expired at 11:59 p.m. Eastern Time on December 6, 2025. No proposals were received prior to the expiration.
  Dec 8, 2025
• Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
  NEW YORK, December 08, 2025--Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood," "we," "us," or "our") today issued the following open letter to the shareholders of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to oppose the proposed sale of the Company to Alcon Inc. ("Alcon") (NYSE: ALC) on transaction terms that remain unchanged following the conclusion of the Company’s flawed and
  Dec 8, 2025
• Is STAAR Surgical Attractive After Multi Year Share Price Slide And DCF Upside?
  Wondering whether STAAR Surgical at around $25 a share is a bargain or a value trap? Let us unpack what the market is really pricing in and what the fundamentals say. The stock is roughly flat over the last year at about 0.3% while still up 5.3% year to date, but those modest gains sit on top of a painful multi year slide of around 58% over three years and nearly 68% over five. That kind of long term drawdown usually reflects shifting expectations around growth and competitive pressure in...
  Dec 7, 2025
• STAAR Surgical (NASDAQ:STAA) Q3 Earnings: Leading The Medical Devices & Supplies - Specialty Pack
  Looking back on medical devices & supplies - specialty stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including STAAR Surgical (NASDAQ:STAA) and its peers.
  Dec 5, 2025
• Broadwood reiterates push for STAAR Surgical board shake-up as Alcon vote nears
  Investing.com -- After a brief cooldown in hostilities, tensions around STAAR Surgical ’s (NASDAQ:STAA) proposed sale to Alcon AG (NYSE:ALC) reignited Tuesday as activist shareholder Broadwood Partners reiterated its push to remove three members from the company’s board ahead of the pivotal Dec.
  Dec 3, 2025
• Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms
  One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.
  Dec 3, 2025
• Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
  NEW YORK, December 02, 2025--Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today announced that it is well along in the multi-step and time-consuming process that is required to call a Special Meeting of Shareholders (the "Special Meeting") at STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) to remove three directors from the Company’s Board of Directors (the "Board"). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to oppose t
  Dec 2, 2025
• Staar Surgical, Gold Royalty See Activist Action
  Activists also report to the SEC on Acadia Healthcare, Butterly Network, National Energy Services Reunited, and Invivyd.
  Nov 26, 2025
• 3 Stocks Possibly Trading At A Discount Of Up To 37.8%
  In the current U.S. market landscape, major stock indexes have recently experienced fluctuations, with notable gains following Nvidia's impressive earnings results and Walmart's strong performance. Amidst these developments, investors may find opportunities in stocks that are potentially trading below their intrinsic value, offering a chance to capitalize on market inefficiencies and economic shifts.
  Nov 20, 2025
• STAAR Surgical reveals board dissent over amended Alcon deal ahead of vote
  Investing.com -- STAAR Surgical Company (NASDAQ:STAA) disclosed new details about board deliberations surrounding its amended $28-per-share sale to Alcon AG (NYSE:ALC), revealing on Monday that the board is no longer unanimous in its support for the revised terms and that CEO Stephen Farrell was unable to secure a price increase before directors voted to proceed.
  Nov 18, 2025
• Exclusive: Broadwood says Alcon’s earnings reveal STAAR bid came from ‘weakness’
  Investing.com -- Alcon AG’s (NYSE:ALC) latest earnings are drawing fire from new acquisition STAAR Surgical ’s (NASDAQ:STAA) largest shareholder, Broadwood Partners, which said the results underscore why the Swiss eye-care company “needs STAAR far more than STAAR needs Alcon.”
  Nov 12, 2025
• How Recent Developments Are Rewriting the Story for STAAR Surgical
  STAAR Surgical’s price target has remained steady, even as several dynamics around the company have shifted. Investors are weighing both upside from ongoing deal negotiations and ongoing uncertainty stemming from shareholder opposition. Readers interested in staying ahead of these developments should follow the evolving situation closely as the narrative continues to change. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value...
  Nov 12, 2025
• 3 Small-Cap Stocks That Fall Short
  Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
  Nov 10, 2025
• Broadwood continues pressure on STAAR board, urges new directors amid go-shop move
  Investing.com -- STAAR Surgical ’s (NASDAQ:STAA) largest shareholder is intensifying calls for board changes after the implantable lens maker agreed last week to revise its merger agreement with Alcon AG (NYSE:ALC) and open a 30-day “go-shop” window to solicit rival offers.
  Nov 10, 2025
• Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
  NEW YORK, November 10, 2025--Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) to Alcon Inc. ("Alcon") (NYSE: ALC).
  Nov 10, 2025
• STAAR’s largest shareholder requests new directors in ongoing Alcon merger dispute
  STAAR has added a 30-day ‘go-shop’ window to its $1.5bn merger with Alcon, which Broadwood wants fresh eyes on to boost shareholder confidence.
  Nov 10, 2025
• STAAR Surgical (STAA): Exploring Current Valuation Perspectives After Recent Share Price Stability
  STAAR Surgical (STAA) shares ended the day slightly lower, slipping 0.3%. Investors may be keeping an eye on recent trading activity given the stock's relatively stable performance over the past month. Longer-term returns remain mixed. See our latest analysis for STAAR Surgical. STAAR Surgical’s 2024 has been a rollercoaster, with the share price gaining just over 10% year-to-date despite a sharp 10% total shareholder return decrease over the past year. Recent momentum seems to be stalling,...
  Nov 9, 2025
• STAAR Surgical opens go-shop window amid shareholder revolt over Alcon deal
  Investing.com -- The controversial merger between STAAR Surgical Company (NASDAQ:STAA) and Alcon AG (NYSE:ALC) is taking on a new form, as the implantable lens maker agreed to revise its merger agreement and actively solicit rival offers amid mounting shareholder backlash.
  Nov 7, 2025
• STAAR Surgical Announces Amendments to Alcon Merger Agreement
  LAKE FOREST, Calif., November 07, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the Company has agreed with Alcon Inc. (SIX/NYSE: ALC) to amend their merger agreement to allow proactive solicitation by STAAR of third-party proposals to maximize value for all STAAR stockholders.
  Nov 7, 2025
• 2 High-Flying Stocks on Our Buy List and 1 We Find Risky
  Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.
  Nov 6, 2025
• Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
  HONG KONG, November 06, 2025--Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
  Nov 6, 2025
• 3 Stocks Under $50 We Keep Off Our Radar
  The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
  Nov 5, 2025
• Staar Surgical: Q3 Earnings Snapshot
  LAKE FOREST, Calif. AP) — Staar Surgical Co. (STAA) on Wednesday reported third-quarter profit of $8.9 million. The Lake Forest, California-based company said it had profit of 18 cents per share.
  Nov 5, 2025
• STAAR Surgical Reports Third Quarter 2025 Results
  LAKE FOREST, Calif., November 05, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025.
  Nov 5, 2025
• Alcon, Broadwood trade blows in fight for STAAR Surgical’s future
  Investing.com -- The takeover battle over STAAR Surgical Company (NASDAQ:STAA) escalated Tuesday as Alcon AG (NYSE:ALC) and Broadwood Partners traded public attacks, marking a more personal turn in the months-long dispute over the company’s $28-per-share sale.
  Nov 4, 2025
• Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
  GENEVA, November 04, 2025--Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
  Nov 4, 2025
• Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
  NEW YORK, November 04, 2025--Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today commented on the investor presentation issued by Alcon Inc. ("Alcon") (NYSE: ALC) regarding its proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR’s outstanding common stock, continues to urge its fellow shareholders to vote on its GREEN Proxy Card "AGAINST" the proposed transaction.
  Nov 4, 2025
• 1 Cash-Burning Stock for Long-Term Investors and 2 We Turn Down
  Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
  Oct 31, 2025
• Alcon rejects raised bid for STAAR Surgical as shareholders revolt
  Investing.com -- STAAR Surgical Company (NASDAQ:STAA) privately asked Alcon AG (NYSE:ALC) to sweeten its $28-per-share takeover offer, but Alcon rejected the request, according to supplemental proxy materials filed late Thursday.
  Oct 31, 2025
• Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
  HONG KONG, October 31, 2025--Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today released the following letter to the Board of Directors of STAAR after its decision to postpone STAAR’s Special Meeting of Stockholders to vote on the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025.
  Oct 31, 2025

STAA Reviews

• ManiaBroker

  Dec 30, 2025

  $STAA Their tech is sharper than my dad's dad jokes. Who knew vision correction could be this cool?

  Buy

• DiamondHands

  Dec 30, 2025

  $STAA This company’s skills in surgery are so sharp, they could probably help you out with your homework too!

  Buy

• BullishVanguard

  Dec 30, 2025

  $STAA Aiming for the stars but landing in mediocrity.

  Sell

• FiscalRogue

  Dec 30, 2025

  $STAA Innovation? More like stagnation—don't get your hopes up.

  Sell

• FOMOKing

  Dec 30, 2025

  $STAA Surgical precision, they’re cutting through the competition like a boss!

  Buy

• OptionSpectre

  Dec 29, 2025

  $STAA If only performance matched the hype.

  Sell

• VolatileViking

  Dec 28, 2025

  $STAA This company must have a knack for staying sharp—kind of like that friend who always gives the best advice, even if it’s unsolicited.

  Buy

• CashCombo

  Dec 28, 2025

  $STAA Correcting vision while also making you feel like you’re starring in your own medical drama. Pass the popcorn!

  Buy

• FinTechFrost

  Dec 26, 2025

  $STAA They help you see better, which is great because some of us need all the help we can get!

  Buy

• TheChartCode

  Dec 25, 2025

  $STAA Vision correction? More like vision perfection. Just don’t forget your glasses for those ‘now I see’ moments!

  Buy

• TickerTyrant

  Dec 25, 2025

  $STAA Not even a surgeon could fix this sinking ship.

  Sell

• TheEarningsBeast

  Dec 25, 2025

  $STAA This stock is that overachiever in class—constantly making headlines but sometimes too cool for the rest of us to handle!

  Buy

• ShortSqueezeX

  Dec 25, 2025

  $STAA These folks are shaping the future of vision—because who doesn’t want to see their crush clearly?

  Buy

• EarningsEcho

  Dec 25, 2025

  $STAA It’s like that movie you never thought would be good but totally had you on the edge of your seat!

  Buy

• BearFighter

  Dec 24, 2025

  $STAA Does anyone really trust an eye company with that name?

  Sell

• BullRunBandit

  Dec 24, 2025

  $STAA Stay sharp with this one, it's got the hustle but needs the right push!

  Buy

• ChartPhantom

  Dec 23, 2025

  $STAA With precision sharper than my math teacher's pencil, this stock is all about cutting-edge solutions. Hope it doesn’t take a ‘stab’ at our wallets!

  Buy

• BagholderPrime

  Dec 23, 2025

  $STAA When it comes to surgery, this company is like the cool doctor that everyone wants—expertise with a side of charm!

  Buy

• OptionCipher

  Dec 22, 2025

  $STAA In the medical tech realm, this one is on the brink of breakthroughs, but the clock is ticking. One miscalculation could spell disaster. Can they deliver?

  Buy

• LazyQuant

  Dec 22, 2025

  $STAA This stock is like a precision surgeon—sharp, focused, and ready to make some serious moves!

  Buy

• PixelBroker

  Dec 20, 2025

  $STAA Their products make sure you don’t just see life, but see it clearly—like finding your glasses after a wild night!

  Buy

• TradeNova

  Dec 20, 2025

  $STAA This one's got mad potential, watch it fly high soon!

  Buy

• MarketGlitch

  Dec 20, 2025

  $STAA In the surgical sector, precision is everything! Can they continue to innovate in this high-stakes market, or will they fall victim to stagnation?

  Sell

• LazyQuant

  Dec 19, 2025

  $STAA This stock could totally star in a reality show called 'Keeping Up with the Profits'—drama and gains included!

  Buy

• StonkSlayer

  Dec 19, 2025

  $STAA Like that one friend who never misses a party—this stock shows up, shines, and leaves everyone impressed!

  Buy

• TraderFury

  Dec 19, 2025

  $STAA Surgical innovations are crucial, but can this player stay relevant in a fast-evolving field? The pressure to perform is relentless—every detail counts!

  Buy

• MarketSavage

  Dec 19, 2025

  $STAA This one's like a vision—great in theory, but a nightmare in practice.

  Sell

• StonkKnight

  Dec 18, 2025

  $STAA They're slicing through challenges like butter, gotta respect that grind!

  Buy

• HODLWarrior

  Dec 17, 2025

  $STAA Surgical moves, always hitting the mark!

  Buy

• TickerTakedown

  Dec 17, 2025

  $STAA This company’s like a magician, turning vision into reality. Just don’t ask it to pull a rabbit out of a hat!

  Sell

• ProfitGremlin

  Dec 17, 2025

  $STAA This joint's got mad potential for those eyeing growth!

  Buy

• TickerTyrant

  Dec 17, 2025

  $STAA Chasing trends, but who’s actually chasing them?

  Sell

• ChartNomad

  Dec 16, 2025

  $STAA This thrilling rollercoaster of innovation has everyone on edge! Each development could skyrocket the company or leave investors biting their nails, unsure of what’s next.

  Buy

• AlphaRogue

  Dec 16, 2025

  $STAA Like a magician with a scalpel, this company makes improvements disappear and patients smile—no rabbits or top hats required!

  Buy

• BullishBard

  Dec 16, 2025

  $STAA Talk about a company with a vision! They’re out here saving eyesight like superheroes, minus the capes and tights. Can I get a round of applause for clear vision?

  Buy

• YOLOHold

  Dec 15, 2025

  $STAA Slicing through the market like a pro, these folks know their craft!

  Buy

• QuantKnight

  Dec 15, 2025

  $STAA With rapid innovations in vision correction technology, staying ahead in this game feels like a race against time. Every advancement can shift the market dynamics overnight!

  Buy

• QuantQuest

  Dec 15, 2025

  $STAA This one’s like a magician; it makes vision correction disappear! Just hope it doesn’t pull a rabbit out of the hat when you least expect it.

  Sell

• YieldSlasher

  Dec 14, 2025

  $STAA Chasing growth like a dog chases its tail.

  Sell

• CapitalRush

  Dec 13, 2025

  $STAA This surgical company is recognized for its precision and cutting-edge medical devices. Its focus on enhancing patient care and commitment to innovation could set it apart in a competitive healthcare market.

  Buy

• CashMeOutside

  Dec 13, 2025

  $STAA Got the moves that impress, keep watchin’ this player!

  Buy

• CapitalFrame

  Dec 13, 2025

  $STAA This company excels in the medical device sector, demonstrating a strong commitment to improving surgical outcomes. Its innovative technologies position it well for growth in an expanding market.

  Buy

• VolatilityViper

  Dec 13, 2025

  $STAA Momentum turning sharply upward.

  Buy

• OptionCipher

  Dec 12, 2025

  $STAA With advancements in healthcare technology moving at lightning speed, this medical firm must stay ahead. Any slip-up could cost them dearly in a ruthless market. Investors are holding their breath!

  Buy

• TradeProtocol

  Dec 12, 2025

  $STAA Surgery just got a makeover—talk about a glow-up! This company is like the beauty guru of the medical world! 💉💖

  Buy

• ChartPilot

  Dec 12, 2025

  $STAA Momentum shifting sharply downward.

  Sell

• StonkKnight

  Dec 12, 2025

  $STAA Lots of trapped longs unloading.

  Sell

• RiskRanger

  Dec 11, 2025

  $STAA This one’s got more ups and downs than my mood on a Monday morning. A little stability wouldn’t hurt, right?

  Sell

• TradeBlaze

  Dec 11, 2025

  $STAA With innovative products catering to a vital healthcare need, this company showcases promising growth prospects as it continues to enhance patient outcomes through advanced technology.

  Buy

• ChartPilot

  Dec 11, 2025

  $STAA Early signs of long-term breakout.

  Buy

• ProfitFang

  Dec 11, 2025

  $STAA Sellers crushing upward attempts.

  Sell

• ProfitLancer

  Dec 11, 2025

  $STAA Downtrend clearly dominant.

  Sell

• DividendJunkie

  Dec 10, 2025

  $STAA Innovation can't mask the lack of decent returns.

  Sell

• AlphaRogue

  Dec 10, 2025

  $STAA This company is sharper than my math skills after a couple of energy drinks!

  Buy

• OptionCipher

  Dec 9, 2025

  $STAA In a field where precision meets urgency, every move counts. With advancing technologies and fierce rivals, will they secure their spot at the forefront?

  Buy

• FiscalRogue

  Dec 9, 2025

  $STAA Bearish price rejection confirmed.

  Sell

• WallStreetBandit

  Dec 9, 2025

  $STAA Supply zones rejecting price sharply.

  Sell

• MarginMarauder

  Dec 9, 2025

  $STAA Strong buying interest at critical levels.

  Buy

• CryptoCobra

  Dec 9, 2025

  $STAA High-quality bullish setup.

  Buy

• CashClown

  Dec 9, 2025

  $STAA Killing it lately, don’t underestimate this player!

  Buy

• ShortKingston

  Dec 8, 2025

  $STAA Making surgical tools sound as cool as a superhero gadget—watch out, villains!

  Buy

• BuyLowBro

  Dec 8, 2025

  $STAA Surgery with a side of style! It’s like fashion week for your eyes. Always in vogue, right?

  Buy

• TradeBlitz

  Dec 7, 2025

  $STAA This company is like a pair of trendy glasses – making everything look sharper and more stylish, even your bank account!

  Buy

• DividendVortex

  Dec 7, 2025

  $STAA This organization is at the forefront of innovation in surgical technologies, constantly seeking to improve procedures and patient care.

  Buy

• StonkDestroyer

  Dec 5, 2025

  $STAA If you like surgical precision in failure, this is your pick.

  Sell

• AlphaDruid

  Dec 4, 2025

  $STAA Innovation is key in this fast-paced industry, but with competitors hot on their heels, will they capitalize on opportunities or get left behind? Tension mounts!

  Buy

• TradePulse

  Dec 4, 2025

  $STAA Extremely bullish confluence detected.

  Buy

• AlgoAce

  Dec 4, 2025

  $STAA Chart looks extremely fragile.

  Sell

• TheAlphaDagger

  Dec 4, 2025

  $STAA Sellers tightening grip on price.

  Sell

• BullishVanguard

  Dec 3, 2025

  $STAA Could someone explain why this is still a thing?

  Sell

• GammaGrind

  Dec 3, 2025

  $STAA Surgery tech vibes are poppin’, this one’s on the rise!

  Buy

• DividendVortex

  Dec 2, 2025

  $STAA As a leader in vision care, this company showcases its dedication to innovation, developing groundbreaking products that significantly enhance patient outcomes in the ophthalmic sector.

  Buy

• BullishSniper

  Dec 2, 2025

  $STAA This company's got more precision than my aim when throwing crumpled paper balls at the trash can—seriously impressive!

  Buy

• OptionNomad

  Dec 1, 2025

  $STAA Medical advancements are booming, but with constant regulatory hurdles, will this company navigate the challenges or get bogged down?

  Sell

• StockStrider

  Dec 1, 2025

  $STAA As a leader in innovative surgical solutions, this company is dedicated to enhancing patient outcomes. Their constant push for advancements in technology underscores their potential for significant market impact.

  Buy

• TendieTitan

  Dec 1, 2025

  $STAA This company knows how to make eyes sparkle and patients smile—talk about vision goals!

  Buy

• EarningsEcho

  Dec 1, 2025

  $STAA This stock is like your favorite superhero—could save the day, but don’t forget that even heroes have bad days!

  Buy

• VolatilityNomad

  Nov 30, 2025

  $STAA Surgery tech that’s not making the cut.

  Sell

• DigitalDividend

  Nov 29, 2025

  $STAA This company's got more precision than a surgeon on a coffee break. Totally sharp!

  Buy

• PnLPhantom

  Nov 29, 2025

  $STAA In the cutting-edge world of medical devices, this company's innovation pace feels like a race against time. Will they lead the pack or get overshadowed by rivals?

  Buy

• CandleKnight

  Nov 28, 2025

  $STAA They're making moves in the surgical space, just watch!

  Buy

• StonkPhantom

  Nov 28, 2025

  $STAA With surgical advancements on the line, the tension is palpable! Every innovation could mean life or death in this industry. Will they lead the charge or fall short? The stakes couldn't be higher!

  Buy

• CashMeOutside

  Nov 28, 2025

  $STAA This one's got the skills to pay the bills, no doubt!

  Buy

• BullBrawler

  Nov 27, 2025

  $STAA Shooting for the stars but landing in mediocrity.

  Sell

• DividendHunter

  Nov 27, 2025

  $STAA Surgical precision? More like surgical disappointment.

  Sell

• TheStockKnight

  Nov 27, 2025

  $STAA Another one hoping for growth while treading water.

  Sell

• BearBreaker

  Nov 27, 2025

  $STAA A surgical company that's not really cutting it anymore.

  Sell

• BearishBoi

  Nov 26, 2025

  $STAA This stock is the cool kid in class, showing everyone how to look sharp while making things better for the rest of us!

  Buy

• StonkRider

  Nov 26, 2025

  $STAA This organization is recognized for its advancements in surgical technology, significantly enhancing procedures and patient outcomes. Its focus on innovation and a strong product line can drive growth in the evolving healthcare market.

  Buy

• IndexPredator

  Nov 25, 2025

  $STAA Every tick of this stock sends shivers down the spine! It’s a high-stakes game where quick decisions could make or break you. Are you ready for the heart-pounding action?

  Buy

• MemeInvestor

  Nov 24, 2025

  $STAA This one helps you see clearer than a pair of new glasses—perfect for spotting opportunity!

  Buy

• BuyLowBoi

  Nov 22, 2025

  $STAA Vision correction game strong, always leveling up their tech.

  Buy

• FiscalFury

  Nov 22, 2025

  $STAA Eyes on the prize with surgical precision, just don’t let it turn into a game of operation with the markets!

  Sell

• StonkKnight

  Nov 21, 2025

  $STAA Eyes on this player, shaping the future like a boss.

  Buy

• CandleKnight

  Nov 20, 2025

  $STAA Got that steady grind, could be a real sleeper hit!

  Buy

• CodeAndCapital

  Nov 19, 2025

  $STAA This company is like the kid who always gets picked first in gym class. Everyone wants a piece of their action!

  Buy

• QuantRift

  Nov 18, 2025

  $STAA With a focus on improving patient outcomes through cutting-edge technology, this organization is making notable progress in the medical device industry. Their innovations could pave the way for increased market adoption.

  Buy

• DividendHunter

  Nov 18, 2025

  $STAA Surgery gadgets? Hope you like overpriced medical risks.

  Sell

• QuantSpecter

  Nov 18, 2025

  $STAA Surgical advancements are crucial, but can this company maintain its edge in a competitive landscape? With every moment counts, this is a heart-racing situation!

  Buy

• TrendHunter

  Nov 18, 2025

  $STAA Surgical precision? More like slashing hopes.

  Sell

• CryptoCobra

  Nov 17, 2025

  $STAA This company is like a wizard with a scalpel—making magic happen in the world of surgery. Just no wand waving, please!

  Buy

• MarginBeast

  Nov 17, 2025

  $STAA Just another overpriced gadget chasing trends.

  Sell

• VolatilityCore

  Nov 16, 2025

  $STAA This surgical company highlights its dedication to advancing patient care through innovative medical devices. Its strong research and development focus positions it well within the evolving landscape of healthcare solutions.

  Buy

• TrendHunter

  Nov 15, 2025

  $STAA Surgery and profits? The odds don't seem favorable.

  Sell

• TradeGoblin

  Nov 15, 2025

  $STAA Vision and precision on deck, they're ready to scale heights like no other!

  Buy

• QuantAssault

  Nov 15, 2025

  $STAA Making surgery feel like a breeze! It's like they put a joystick in the surgeon's hands. Game on!

  Buy

• CapitalCrusher

  Nov 13, 2025

  $STAA Think of this company as the superhero of vision—always helping you see the brighter side of things!

  Buy

• TradeProtocol

  Nov 13, 2025

  $STAA Surgery for your eyes? I just can't get over how my glasses still manage to look cool though!

  Sell

• ShortSavage

  Nov 13, 2025

  $STAA With advancements in surgical technology booming, will they be the ones leading the charge? Stakeholders are eager for progress but wary of setbacks. The tension is palpable!

  Buy

• TickerTyrant

  Nov 13, 2025

  $STAA Surgery might improve sight, but not your investment outlook.

  Sell

• BearHunter

  Nov 13, 2025

  $STAA Getting in on this feels like catching the last slice of pizza – thrilling and totally worth it!

  Buy

• OptionShadow

  Nov 12, 2025

  $STAA Known for its innovative medical devices, this firm is addressing critical needs in vision care. Their commitment to research and development promises to drive future growth and enhance patient outcomes.

  Buy

• DividendDemon

  Nov 11, 2025

  $STAA If this stock were a surgeon, it would specialize in eye surgeries—because it’s all about making clear visions a reality! Just keep the scalpel away from my pizza.

  Buy

• TradeBlitz

  Nov 11, 2025

  $STAA Surgery sounds intense, but if they keep cutting through the competition, they’ll be the new superheroes in scrubs!

  Buy

• TradeMatrix

  Nov 11, 2025

  $STAA In the competitive medical device market, innovation is the name of the game. If they can't keep up, their market share could disappear faster than you can blink!

  Buy

• WallStreetVandal

  Nov 10, 2025

  $STAA Surgery can be scary, but this company's prospects are scarier.

  Sell

• DividendJunkie

  Nov 10, 2025

  $STAA Innovative? More like just another gimmick with a fancy name.

  Sell

• TickerTyrant

  Nov 10, 2025

  $STAA Surgery tech? Looks like a risky gamble.

  Sell

• CashKiller

  Nov 9, 2025

  $STAA Surgery without anesthesia—this company hurts.

  Sell

• OptionOutlaw

  Nov 8, 2025

  $STAA Surgery and price cuts, not a good mix.

  Sell

• WallStreetWraith

  Nov 8, 2025

  $STAA Trying hard to look like a leader while dragging its feet.

  Sell

• BuyLowBro

  Nov 8, 2025

  $STAA This stock is like a laser pointer for cats—everyone’s chasing after it, but will it land on something worth catching?

  Buy

• StockShotz

  Nov 8, 2025

  $STAA They’re surgery specialists, but let’s hope their stock doesn’t need a doctor anytime soon!

  Sell

• TradePredator

  Nov 8, 2025

  $STAA This stock is about as exciting as watching paint dry.

  Sell

• BullRunBoi

  Nov 8, 2025

  $STAA These surgical pros are snappin' up the market—gotta watch 'em shine.

  Buy

• QuantAssault

  Nov 8, 2025

  $STAA This company could really help you see the brighter side of life — literally! They’re basically the cool optometrist of the stock market.

  Buy

• TrendScript

  Nov 7, 2025

  $STAA Even my coffee is less jittery than this price action. Who.

  Buy

• QuantKnight

  Nov 2, 2025

  $STAA This rally just cured my Monday blues. Feels like this ticker just.

  Buy

• SignalStriker

  Nov 1, 2025

  $STAA I'm not saying it's mooning, but it's definitely packing a.

  Buy

• QuantumBroker

  Oct 23, 2025

  $STAA range no clear soon soon run no maybe here it soon-ish now hard heavy fast heavy vol soon vibes printing fast trigger feels

  Buy

• ShortRaid

  Oct 16, 2025

  $STAA here imo steady diamond smooth charts risk eyes levels tight steady sentiment vibes check loud alpha watching today humming it steady tax imo

  Buy

• QuantumBroker

  Oct 15, 2025

  $STAA my smells this like eyes hurts

  Sell

• RiskRanger

  Oct 9, 2025

  $STAA I blinked and lost my lunch money. Honestly, I'm just here.

  Buy

• TraderFury

  Oct 8, 2025

  $STAA Volume so low it's whispering sweet nothings. Even my coffee is less jittery than.

  Buy

• ProfitGremlin

  Oct 8, 2025

  $STAA Momentum so steady it could teach yoga. This setup is giving main character energy.

  Sell

• MoneyMage

  Oct 5, 2025

  $STAA than crypto deader trend's winter

  Sell

• BearEater

  Sep 28, 2025

  $STAA tape check on fire sentiment today feels today macro smart risk it money hands patience gap nimble maybe imo volume soon risk soon hands gap buzzing diamond whispers risk

  Buy

• LiquidKnight

  Sep 21, 2025

  $STAA Perfect setup for disappointment right here. I blinked and lost my lunch money.

  Sell

• ShortCircuit

  Sep 11, 2025

  $STAA This setup is giving main character energy. This chart looks like it just had an energy drink.

  Sell

• TradeMatrix

  Sep 11, 2025

  $STAA Chart's climbing like it heard good news from the universe. Even my risk management is smiling today.

  Sell

• RiskAssassin

  Sep 6, 2025

  $STAA breakout soon pumping steady on clear tape risk clean theta charts volume maybe mode humming hands fire flows bull

  Buy

• CandleBinary

  Sep 6, 2025

  $STAA on go vibes alpha smooth hard trigger range run whispers spike crushing hard levels humming

  Buy

• FUDCrusher

  Sep 2, 2025

  $STAA fake rally even beyond trend repair broken dumpster can't a fire

  Sell

• BullishSniper

  Aug 22, 2025

  $STAA dip weak my keeps eyes like hurts this stock chart just more this weak dipping hands?

  Sell

• ChartNomad

  Aug 17, 2025

  $STAA every crypto bounce than sold gets winter deader instantly trend's

  Sell

• MarketRender

  Aug 15, 2025

  $STAA now range trigger vibes heavy theta trigger wild sentiment now humming maybe volume on volume tape talking sentiment levels spike money hard eyes smart soon steady printing levels

  Buy

• DividendFrame

  Jul 4, 2025

  $STAA whispers alpha fire hard tight clean check watching macro here clean noise pumping gap

  Buy

• StonkPhantom

  May 23, 2025

  $STAA dive supply heavy diamond level-to-level macro cat clear weak charts soon doom dumping noise nasty flows fast

  Sell

• CashCombo

  Mar 28, 2025

  $STAA gains spicy run fast steady rocket patience today run printing

  Buy

• TheFiscalShade

  Mar 24, 2025

  $STAA flows liquidity bagholder queued clean charts cliff nimble flows heavy hard fast sentiment

  Sell

• ChartNomad

  Dec 27, 2024

  $STAA queued nasty whispers feels out macro vibes steady level-to-level stops wall cat heavy watching

  Sell

• PortfolioGremlin

  Oct 29, 2024

  $STAA session ruggy loud volume rip out patience patience dumping ugly

  Sell

• AlphaHawk

  Oct 19, 2024

  $STAA steady city lower risk bagholder hurts smart soon heating on maybe dumping trigger no city rip

  Sell

• TheChartCode

  Oct 5, 2024

  $STAA diamond soon staying nimble spike vibes bounce diamond macro flows oversold risk on

  Buy

• GainsOverBrains

  Sep 27, 2024

  $STAA stops choppy queued bear steady feels vol loud wild patience patience money trigger buzzing mode mess queued

  Sell

• MissionOverlord

  May 23, 2024

  $STAA smart out tax clear patience risk today hard vol tbh hedges keeping lows today out here whoa clean maybe

  Sell

• TradeFrenzy

  May 6, 2024

  $STAA heat tight flows crushing keeping trigger ath volume king strong buzzing on tight

  Buy